Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti
ASCO 2021: Pembrolizumab (Pembro) plus Axitinib (Axi) Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Results from 42-Month Follow-up of KEYNOTE-426
ASCO 2020: Phase II trial of Lenvatinib plus Pembrolizumab for Disease Progression after PD-1/PD-L1 Immune Checkpoint Inhibitor in Metastatic Clear Cell Renal Cell Carcinoma
PDF) The use of serial circulating tumor DNA (ctDNA) to detect resistance alterations in progressive metastatic breast cancer
Frontiers Role of metastasectomy in the management of renal cell carcinoma
PDF) A Systematic Review of Clinical Practice Guidelines for Managing Pulmonary Toxicities Caused by Immune Checkpoint Inhibitors: Quality of Treatment Recommendations and Differences in Management Strategies Between Guidelines
ASCO 2020: Researchers underscore efficacy of pembrolizumab plus
Abeloff's Clinical Oncology [6 ed.] 0323476740, 9780323476744
Elizabeth Plimack Fox Chase Cancer Center - Philadelphia PA
PDF) Emozioni scoperte: A COLLECTION OF AUTOBIOGRAPHICAL TEXTS BY ONCOLOGIC PATIENTS
ASCO GU 2022: Efficacy and Safety of Lenvatinib Plus Pembrolizumab Versus Sunitinibin the East Asian Subset of Patients With Advanced Renal Cell Carcinoma From the Phase 3 CLEAR Trial
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial - ScienceDirect
ASCO GU 2021: Outcomes For Patients In the Pembrolizumab+Axitinib Arm With Advanced Renal Cell Carcinoma Who Completed Two Years Of Treatment In The Phase III KEYNOTE-426 Study
ASCO 2021: Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma: Results from 42-Month Follow-up of KEYNOTE-426
ASCO 2021: Pembrolizumab Versus Placebo as Post-Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma: Randomized, Double-Blind, Phase III KEYNOTE-564 Study
